Roberto Vargas

Has grant

Assistant Professor

Cleveland Clinic

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Research Cancer Research professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Evolutionary experimentation and radio-genomics in endometrial cancer.

Open Date: 2022-07-01

Close Date: 2025-06-30

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Defne Bayik

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES

View details

Floor Backes

The Ohio State University Comprehensive Cancer Center

UNITED STATES

View details

Casey Cosgrove

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Roberto Vargas

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

Association of Clinical Trial Participation with Improved Overall Survival for Recurrent, Platinum-Resistant Ovarian Cancer

Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer

Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer

Association between adrenal-restrictive HSD3B1 inheritance and hormone independent subtypes of endometrial and breast cancer.

Analysis of patient experiences with gestational trophoblastic neoplasia reported on Instagram social media

Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer

Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma

Collaborators (3)

Defne Bayik

Floor Backes

Casey Cosgrove

Make your next move.

Roberto Vargas

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series

Association of Clinical Trial Participation with Improved Overall Survival for Recurrent, Platinum-Resistant Ovarian Cancer

Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&amp;8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer

Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer

Association between adrenal-restrictive HSD3B1 inheritance and hormone independent subtypes of endometrial and breast cancer.

Analysis of patient experiences with gestational trophoblastic neoplasia reported on Instagram social media

Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer

Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma

Collaborators (3)

Defne Bayik

Floor Backes

Casey Cosgrove

Make your next move.

Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer